Daily Stock List
Duma Energy Corp. (DUMA)
Alternative Energy, FeedBlitz, MissionIR, SeriousTraders, and Tiny Gems reported earlier on Duma Energy Corp. (DUMA), and we are highlighting the Company as "One to Watch" this week here at the QualityStocks Daily Newsletter.
Headquartered in Houston, Texas, Duma Energy Corp. engages in the acquisition, exploration, development, and production of oil and natural gas properties in the continental U.S - on and offshore. Additionally, the Company has a significant interest (39 percent) in a 5.3 million-acre concession in the Republic of Namibia in southern Africa. Duma Energy plans to continue increasing their domestic revenues and cash flow to fuel their aggressive growth through acquisition and participation in high impact international projects.
The Company is actively producing and generating revenue from oil and gas in Texas, Illinois, and Louisiana. They earlier projected domestic production to exceed 1,000 barrels of oil equivalent per day (boepd) by the end of 2012. The Company projects 2,500 (boepd) by the end of 2013. Their primary goals for fiscal year 2013 and beyond are positive cash flow and positive earnings.
Duma successfully drilled their first exploration well in Trinity Bay, Texas. It proves up a large 3D seismic fault block potentially containing over 5 million barrels of oil. In addition, their plan is to conduct more studies of the Owambo Basin concession in Namibia. The basin appears to have all of the key ingredients for becoming a major oil province. This includes good reservoir and source rocks that extend into southern Angola.
For the fourth quarter ended July 31, 2012, Duma Energy saw Production (net) increase 38 percent to 30.24 Mboe from 21.99 Mboe in the third quarter. Revenue for the quarter increased to $1.89 million. Cash flow from operations for the quarter was up significantly to $1.04 million.
In early December 2012, Duma Energy announced that they received (from Hydrocarb Energy Corp.) additional results from a recent field outcrop study on their concession in northern Namibia. Final lab analyses have indicated significant reservoir porosity and the presence of degraded crude oil.
In-house resource estimates at the structural Oponono Prospect range from 235 million (P90) up to a potential 1.1 billion (P10) barrels of oil. The estimation of P50 resources at Oponono Prospect are 650 million barrels of oil. Additional prospects have undergone identification including reefs and a number of structural traps.
We have Duma Energy Corp. (DUMA) in our sightlines as "One to Watch" this week here at the QualityStocks Daily Newsletter.
Duma Energy Corp. (DUMA), closed Monday's trading session at $2.15, up 8.59%, on 9,076 volume with 16 trades. The average volume for the last 60 days is 4,242 and the stock's 52-week low/high is $1.10/$4.00.
Hanover Portfolio Acquisitions, Inc. (HVPA)
Today we are highlighting Hanover Portfolio Acquisitions, Inc. (HVPA), as "One to Watch" this week here at the QualityStocks Daily Newsletter.
Hanover Portfolio Acquisitions, Inc. (HPA) is a company that consists of two business segments. One is a debt portfolio management company and the other is an intellectual property (IP) management and commercialization company. On March 14, 2012, HPA entered into a Share Exchange Agreement with IP Resources International, Inc. (IPR) and their certain shareholders. Because of the Agreement, the former shareholders of IPR now own approximately 89 percent of the Company and their Officer and Directors constitute the majority of the Officers and Directors of the Company. HPA's shares trade on the OTC Bulletin Board.
The acquisition constitutes a reverse acquisition, since the shareholders, offices, and directors of IPR have control of the Company. IPR is the accounting acquirer and HPA is the accounting acquiree. IPR is an intellectual property management firm that specializes in the commercialization of innovative technologies by way of Joint Ventures (JVs) and international licensing. IPR specializes in the commercialization of technologies within the healthcare, energy, consumer electronics, and internet industries.
HPA's debt portfolio management segment purchases defaulted, unsecured, consumer receivables in the secondary market. This segment garners revenue through collections using an outsourced collection network and through the strategic resale of portfolios. The segment acquires credit card receivable portfolios at significant discounts to the total amounts owed by the debtors, purchasing defaulted consumer receivable portfolios from creditors and others through privately negotiated direct sales.
HPA's intellectual property management and commercialization segment is operated through their wholly owned subsidiary, IP Resources International (IPR). IPR mainly concentrates on licensing diverse commercially desirable technologies and patents from companies that need operating capital or that need help commercializing their technology and sublicense such technology in designated territories (primarily outside the U.S.). This segment acquires exclusive licenses for marketable technology usually without the payment of any upfront license fee to the licensor and thereafter, to sub-license the technology in the designated foreign markets (primarily Asia, Europe, and Brazil).
Today, HPA's wholly owned subsidiary IPR announced that they are in discussions with multiple technology companies to expand their growing intellectual property (IP) portfolio further. IPR is ready to unlock value in the $237 billion IP licensing market. The growing IP portfolio includes Stem Cell, Cardiac, and 3D Display technologies. IPR acquires rights primarily of market-ready technologies and products. They work to monetize the IP via joint ventures and domestic and international sub-licensing in the largest and fastest growing global markets.
We're tracking Hanover Portfolio Acquisitions, Inc. (HVPA) on our radar screens as "One to Watch" this week here at the QualityStocks Daily Newsletter.
Hanover Portfolio Acquisitions, Inc. (HVPA), closed Monday's trading session at $0.32, up 18.52%, on 849,328 volume with 287 trades. The average volume for the last 60 days is 267 and the stock's 52-week low/high is $0.27/$0.35.
A.P. Pharma, Inc. (APPA)
Real Pennies reported today on A.P. Pharma, Inc. (APPA), Profit Confidential, PennyTrader Publisher did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Redwood City, California, A.P. Pharma, Inc. is a specialty pharmaceutical company whose shares trade on the OTC Bulletin Board. The Company is developing products using their proprietary Biochronomer™ polymer-based drug delivery platform. The design of this drug delivery platform is to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
A.P. Pharma's lead product, APF530, is undergoing development for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). CINV is a leading cause of premature discontinuation of treatment. The Company resubmitted their New Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration in September 2012. A.P. Pharma has been assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2013. In addition to APF530, A.P. Pharma has a pipeline of other product candidates that use the Biochronomer™ technology.
APF530 contains the 5-HT3 antagonist granisetron formulated in A.P. Pharma's proprietary Biochronomer™ drug delivery system that allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. The design of this five-day range is to cover the delayed phase of CINV; currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for APF530 because physicians, based on a well-established record of safety and efficacy, extensively prescribe it.
Recently, A.P. Pharma announced the appointment of Mr. Joel Schaedler as Vice President of Market Access and Mr. Daniel Martin as Vice President of Marketing. Mr. Schaedler will be responsible for A.P. Pharma's market access programs for APF530, if approved. Mr. Martin will lead the marketing efforts for APF530.
Mr. Schaedler brings more than 17 years of specialty pharmaceutical and healthcare distributor experience to A.P. Pharma. Most recently, he was the Senior Vice President of Business Development at P4 Healthcare (acquired by Cardinal Health in 2010). Mr. Martin brings 14 years of diverse health care industry experience and almost nine years of oncology marketing experience to A.P. Pharma. Most recently, he was the head of US marketing at Dendreon.
A.P. Pharma, Inc. (APPA), closed Monday's trading session at $0.61, up 1.67%, on 1,536,626 volume with 270 trades. The average volume for the last 60 days is 445,431 and the stock's 52-week low/high is $0.17/$0.78.
East Asia Minerals Corp. (EAS.V)
We are highlighting East Asia Minerals Corp. (EAS.V) today, here at the QualityStocks Daily Newsletter.
Trading on the TSX Venture Exchange, East Asia Minerals Corp. is an Asian-based, Canadian mineral exploration company. East Asia has gold and copper exploration properties in Indonesia, and uranium exploration properties in Mongolia. The Company has an aggressive exploration, acquisition and growth strategy. East Asia Minerals has their corporate headquarters in Vancouver, British Columbia.
In Indonesia, the Company has a 70 percent to 85 percent interest in three advanced gold and gold-copper properties located in Aceh Province, Sumatra, and Sangihe Island, North Sulawesi. East Asia Minerals owns six uranium properties, including the advanced Ingiin-Nars, Ulaan Nuur and Enger uranium projects, and two phosphate properties in Mongolia.
The Indonesian properties contain several advanced projects with drill identified mineralization and the potential to host multi-million ounce near surface gold resources. During 2008, East Asia Minerals strengthened their Mongolian portfolio by acquiring additional uranium and phosphate licenses. The Company controls 100 percent of all new licenses. Highlights of the 2008 exploration efforts include completion of soil gas surveys on several uranium prospects, identifying two discrete anomalies of high priority on each of two project areas.
In early December, East Asia Minerals announced that they began drilling on Phase one of the 4,600-meter drill program at Sangihe Island on the Bawone, Binebase sites, plus the highly prospective Taware Valley/Sedi site. This is the execution of the program that was previously announced in October 2012 to follow up on phase one and phase two drilling programs completed in previous years at the Binebase and Bawone zones. The estimated total cost for the drilling and assaying program is $2.8 million.
In addition, in December, East Asia Minerals announced that Mr. Dave Anthony received appointment to the Board of Directors. Further to the Company's news release of December 11, 2012, in which they announced that Mr. Anthony was stepping down as the Chief Operating Officer and agreed to become a Director when a position became available, East Asia Minerals announced that such a Board position was made available and Mr. Anthony was appointed on December 20, 2012. Mr. Anthony will continue to provide his broad expertise in mineral exploration, development and operations at the Board level.
East Asia Minerals Corp. (EAS.V), closed Monday's trading session at $0.23, up 17.95%, on 322,650 volume. The stock's 52-week low/high is $0.13/$1.01.
Global Security Agency, Inc. (GSAG)
OTCtipReporter, PennyStockScholar, Michael Stone, PickPennyStocks, Research Driven Alerts, Growing Stocks Reports, and SmallCapInvestorDaily reported recently on Global Security Agency, Inc. (GSAG), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2006, Global Security Agency, Inc. is a company that provides global executive protection. They provide security and risk management services for individuals, corporations, and other entities worldwide. The Company formerly went by the name Belvedere Resources Corp. They changed their name to Global Security Agency, Inc. in January of 2010. The Company (listed on the OTCQB) has their headquarters in Conroe, Texas.
Global Security Agency is a licensed private protection agency consisting of career law-enforcement officers, military and specialized personnel. All of their employees are CCT (close combat trained) certified, with firearms and other weaponry. The Company's assurance is that a client's executives, celebrities and dignitaries will arrive, and will have the benefit of a highly trained security detail with them.
The Company's commitment is to on-site protection that ensures immediate and instant response to any threat against a client and their family or property. Global Security Agency has specialized security capacity, home security, event protection and coverage, workplace violence, employee termination, labor disputes, board meeting, executive protection and kidnapping resolutions.
Traditionally, the Company has been the leading provider in logistics, support training, security intelligence work and risk analysis for corporations, and families around the world. They are now offering the same expertise that has been available to their corporate clients to family law practitioners, and their clients in the State Of Texas. Concerning Family Law Services, they offer all civil process services (subpoenas, citations, and more). They also provide private and forensic investigations; personal protection; Training: In Home CHL Training; Risk & Threat Assessments, and 24/7 Private Security.
Recently, Global Security Agency announced that they selected a group of Asian Cultural experts to form a Selection Committee to make the recommendation to the Board on their three best choices for the Global Security Agency (China) division Agency Director position. The GSAC Agency Director will be a certified contractor within China. In addition, the Company recently announced that they signed a Support Services Agreement with Pan Asian Chemicals, a certified contractor within China. Their client base is multinational chemical and energy companies.
Global Security Agency, Inc. (GSAG), closed Monday's trading session at $0.0061, down 10.29%, on 3,350,582 volume with 47 trades. The average volume for the last 60 days is 797,137 and the stock's 52-week low/high is $0.002/$0.11..
AdvanSource Biomaterials Corp. (ASNB)
Nebula Stocks reported previously on AdvanSource Biomaterials Corp. (ASNB), here at the QualityStocks Daily Newsletter.
AdvanSource Biomaterials Corp. manufactures advanced polymer materials providing critical characteristics in medical device design and development. These biomaterials are used in devices designed for treating a broad array of anatomical sites and disease states. The Company's business model leverages their proprietary materials science technology and manufacturing expertise to expand their product sales and royalty and license fee income. AdvanSource Biomaterials has their corporate headquarters in Wilmington, Massachusetts.
Specializing in polyurethane technologies, the Company offers a variety of material formats for use in long and short-term implants and disposable products. Their materials can be customized to meet an extensive range of mechanical properties with product extensions to include radiopaque. The Company's expertise lies in the synthesis and formulation of polymeric materials with an extensive range of physical and chemical properties. These materials possess unique characteristics such as biocompatibility and biodurability. They can be tailored for specific properties such as lubricity and antimicrobial formats.
Their materials include polycarbonate and polyether based polyurethanes, liquid polymers, hydrophilic solutions and extrudable grade materials, echogenic coatings, antimicrobial materials, dissimilar material bonding agents, colorant technologies, and a variety of additional TPU's and elastomers. Services including prototype coating and colorant technologies are also available.
AdvanSource Biomaterials manufactures and sells their custom polymers under the trade names ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, and PolyBlend. Conventional polymers are susceptible to degradation resulting in catastrophic failure of long-term implantable devices such as pacemaker leads. The design of ChronoFlex and ChronoThane polymers are to overcome such degradation and reduce the incidents of infections associated with invasive devices.
The Company manufactures and sells their proprietary HydroThane polymers to medical device manufacturers that are evaluating HydroThane for use in their products. HydroThane is a thermoplastic, water-absorbing, polyurethane elastomer. AdvanSource's PolyBlend is a family of exceptionally soft, aromatic polyurethane elastomeric alloys. These can be used as a substitute for natural rubber or latex in many applications.
AdvanSource Biomaterials Corp. (ASNB), closed Monday's trading session at $0.033, even for the day, on 16,006 volume with 5 trades. The average volume for the last 60 days is 21,188 and the stock's 52-week low/high is $0.0101/$0.1318.
Dakota Territory Resource Corp. (DTRC)
UltimatePennyStock reported earlier on Dakota Territory Resource Corp. (DTRC), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
A Nevada Corporation, Dakota Territory Resource Corp. engages in the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company's Management Team consists of senior professionals, each with more than 30 years business experience and varied expertise in exploration, project development, operations management and finance. Dakota Territory Resource is based in Reno, Nevada; the Company lists on the OTC Market's OTCQB.
Dakota Territory maintains 100 percent ownership of the 1,612 acre Blind Gold Property located approximately three miles northwest and on structural trend with the historic Homestake Gold Mine. Mr. Richard Bachman, President and CEO of Dakota Territory Resource managed Homestake's Black Hills exploration program of the 1980s and 1990s. He was responsible for the drilling of diamond drill core holes that document Homestake iron-formation underlying the Blind Gold Property. Dakota Territory believes that the existence of Homestake iron-formation under the younger Phanerozoic-age rocks covering the Blind Gold Property presents a significant exploration opportunity. The Company believes the repeat of the Homestake style gold mineralization is not only possible, but has already been demonstrated to occur down plunge, just south of the Blind Gold Property.
Today, Dakota Territory Resource announced that the Company has substantially increased their property holdings via the acquisition of three groups of unpatented lode mining claims covering approximately 853 acres in the Black Hills of South Dakota. The property acquisition is in the heart of a district that has produced approximately 50 million ounces of gold over the past 135 years and is to the west, south and southeast of the Company's Blind Gold Property. Dakota Territory has increased the size of their land package in the Black Hills by approximately 50 percent to almost 2,466 acres in total, with the addition of the new property.
Dakota Territory Resource acquired the property from Black Hills Gold Exploration, LLC on December 31, 2012, for a purchase price of one million restricted common shares of Dakota Territory valued at $0.15 per share, or $150,000.00.
Dakota Territory Resource Corp. (DTRC), closed Monday's trading session at $0.14, down 6.67%, on 7,996 volume with 2 trades. The average volume for the last 60 days is 4,933 and the stock's 52-week low/high is $0.01/$0.49.
Rainmaker Systems, Inc. (RMKR)
Penny Detectives, Wall Street Resources, SmarTrend Newsletters, and Stock Stars reported earlier on Rainmaker Systems, Inc. (RMKR), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Rainmaker Systems, Inc. is a leading global cloud e-Commerce company headquartered in Campbell, California. They help multi-national companies address the Business-2-Business (B2B) market by maximizing sales revenue for their products and services. The Rainmaker e-Commerce platform can undergo enhancement with Rainmaker customer assist agents to maximize revenue and customer satisfaction through the entire customer life cycle. Rainmaker Systems lists on the NASDAQ Capital Market.
The Company collaborates with multi-national enterprises that sell software and Software as a Service (SaaS) solutions to their B2B markets. Rainmaker Systems provides customized multi-channel e-business solutions on a worldwide basis supporting multiple payment methods, currencies and language capabilities. They offer a flexible, international solution to automate clients' recurring revenue model, manage the subscriber lifecycle, and increase their customer lifetime value. This is whether a client sells online services, cloud-based, physical or digital products.
This past November, Rainmaker Systems announced a new agreement with Oracle to provide sales services to increase Oracle's partner base on a worldwide level to 32 countries. The Company will identify Resellers who aren't currently selling Oracle products, qualify them based on Oracle's needs and recruit them into the Oracle Partner Network. Rainmaker was chosen for their ability to meet customer business objectives via a refined, scalable, business process and their cloud-based, multi-channel strategy to improve global sales.
Recently, Rainmaker Systems announced the sale of the Company's Manila call center to Shore Solutions, Inc. on December 17, 2012. Rainmaker decided to divest their Manila call center, as the operation no longer fits the long-term strategic plans of the Company. For continuity and continued reach in the region, part of their agreement with Shore is to continue to use some of the key services they utilize today. The sale will result in increased gross margins and have a positive cash flow impact. The sale is an important step in Rainmaker Systems' concentrated focus on cloud e-Commerce enhanced by customer assist agents.
Rainmaker Systems, Inc. (RMKR), closed Monday's trading session at $0.81, up 2.52%, on 2,100 volume with 4 trades. The average volume for the last 60 days is 68,960 and the stock's 52-week low/high is $0.551/$1.37.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.22, up 15.79%, on 229,745 volume with 65 trades. The stock’s average daily volume over the past 60 days is 134,248, and its 52-week low/high is $0.161/$0.68.
International Stem Cell Corp. reported some great news today as positive top line efficacy results come back from the pre-clinical in vivo liver study designed to test the therapeutic equivalence of the company's human parthenogenetic stem cell (hpSC)-derived hepatocytes to adult liver cells. This data is "very encouraging," according to Dr. Andrey Semechkin, CEO and Co-chairman of ISCO, as it gives strong indication that the company's technology will obtain serious traction in the treatment of metabolic liver diseases, including Crigler-Najjar Syndrome (CNS).
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Positive Animal Efficacy Results in Liver Disease Program
International Stem Cell Corporation to Participate in Biotech Showcase 2013 on January 7th
Lifeline Skin Care a Subsidiary of ISCO Announces New Sales and Multi-Media Marketing Campaigns
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0335, up 8.06%, on 4,212,528 volume with 115 trades. The stock’s average daily volume over the past 60 days is 2,019,765, and its 52-week low/high is $0.0275/$0.179.
Advaxis, Inc. announced today that the company will be offering a comprehensive presentation at the highly influential, 6th Annual OneMedForum, in San Francisco, CA, this Tuesday, January 8 at 2pm (PST). Advaxis will take a look at the range of clinical-stage biotech work in immunotherapies for cancer and infectious diseases currently being done at the company and will be making their complete presentation in the stately Windsor Room of the Sir Francis Drake Hotel - including a close look at the company's lead construct, ADXS-HPV. ADXS-HPV was selected as the Best Therapeutic Vaccine approved/in development at the recent 5th Annual Vaccine Industry Excellence Awards.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Present at the 6th Annual OneMedForum
Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.29, on 10,000 volume with 6 trade. The stock’s average daily volume over the past 60 days is 9,602, and its 52-week low/high is $0.18/$1.87.
GlobalWise Investments, Inc. reported signage today of a strategically significant channel sales partnership with Arlington, VA-based provider of the comprehensive Intelligent Process Management (IPM) suite, Iron Data Solutions, Inc. CEO of GWIV, William "BJ" Santiago, hailed the channel partnership as another key vector for expanding the company's scope in both sectors and noted how Iron Data's proven ability to transform the way government agencies control data flow and management information, will dovetail exceptionally well with GWIV's own cloud-based Enterprise Content Management expertise.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Enters New Channel Sales Partnership With Iron Data
GlobalWise Announces Board Changes
GlobalWise Channel Partner Sycle.net Continues to Deliver New Clients
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.03, up 3.45%, on 116,770 volume with 6 trades. The stock’s average daily volume over the past 60 days is 234,887, and its 52-week low/high is $0.01/$0.07.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Achieves Current Information Status on OTC Markets
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
Bergamo Acquisition Updates Financials
International Stem Cell Corporation, a company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs), today reported positive top line efficacy results from its pre-clinical in vivo liver study. The main goal of this study was to demonstrate the therapeutic equivalence of human parthenogenetic stem cell (hpSC)-derived hepatocytes to adult liver cells as a prerequisite for using such cells in the treatment of metabolic liver diseases, including Crigler-Najjar Syndrome (CNS).
CNS is a rare inherited disorder in which bilirubin cannot be broken down by the liver. The build-up of this toxic compound can result in damage to the brain, muscles, and nerves, as well as eventually cause death. Current treatment paradigms for CNS include phototherapy and blood transfusions, but these do not treat the underlying cause of the disease. Hepatocyte transplantation has emerged as a therapeutic strategy, and has been successfully applied to treat patients with CNS, however the extremely limited availability of human livers and therefore of donated primary hepatocytes makes a stem cell based approach attractive.
The results of this efficacy study demonstrate that the hpSC-derived hepatocytes engraft in the liver of Gunn rats and perform in a similar manner to primary human hepatocytes. The Gunn rat is a well-established model of CNS and has been used extensively to study bilirubin toxicity and hepatocytes transplantation. Furthermore, the study indicates that a single intrasplenic injection of hpSC-derived hepatocytes results in a change in the plasma indirect bilirubin level equivalent to that achieved by injecting primary hepatocytes. Establishing the equivalence of hpSC-derived and donor-derived hepatocytes in their ability to metabolize bilirubin supports the thesis that hpSC-derived hepatocytes can be used therapeutically as a substitute for donated primary liver cells.
“Achieving this milestone is very encouraging,” stated Dr. Andrey Semechkin, CEO and Co-chairman of ISCO. “These results suggest that hpSC-derived hepatocytes could be a well suited alternative to donated primary hepatocytes as a source of cells in clinical applications including the treatment of Crigler-Najjar Syndrome.”
For more information on the company and its hpSC technology, visit www.internationalstemcell.com.
Advaxis, a biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, announced this morning that it will be presenting at the 6th Annual OneMedForum on January 8th at 2pm PST in the Windsor Room of the Sir Francis Drake Hotel in San Francisco.
The biotech company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases.
For more information on Advaxis, visit www.advaxis.com
Today before the opening bell, GlobalWise Investments and its wholly owned subsidiary Intellinetics, a leading-edge technology company focused on the design, implementation, and management of cloud-based Enterprise Content Management (“ECM”) systems, announced the signing of a new channel sales partnership with Iron Data Solutions, Inc. (www.irondata.com).
Founded in 2001 to respond to the increasing demand for cost effective business transaction software and services, Iron Data today offers a comprehensive suite of solutions that assess, improve, manage, and monitor challenging operational process issues for clients in the public sectors. Iron Data has more than 400 employees across 11 offices around the U.S. and the world, including Amsterdam, Toronto and Shenzhen, China.
“Iron Data represents another fantastic channel partner who can further expand our scope in both the public and private sector through their technological expertise and established relationships,” stated William “BJ” Santiago, CEO of GlobalWise. “Iron Data has been a proven leader in transforming how government agencies control dataflow and manage information. We are actively working to secure a large government client now and anticipate announcing a new contract with the organization soon. GlobalWise looks forward to working with Iron Data and anticipates many more client opportunities over the coming quarters.”
“We deeply value our government clients and relationships,” commented Tom Gottleib, Vice President of Iron Data. “It was vitally important we found an ECM cloud-based provider who understood the mission critical and privacy needs within the government sector. GlobalWise has served these types of clients since their inception and has a rich and proven legacy to complement our reputation for implementing process management and business automation solutions that reduce waste, fraud and abuse.”
For more information on GlobalWise Investments, visit www.GlobalWiseInvestments.com
When Warren Buffett first took control of Berkshire Hathaway, he effectively turned the company around by redirecting its dwindling resources toward the careful purchase of other companies. In much the same mold, Bergamo Acquisition targets a diversified portfolio of companies for sole acquisition or co-investment alongside other investors such as private equity funds, hedge funds, investment banks, and other institutions.
Bergamo Acquisition plans to effect management buy-outs, friendly mergers, and value-accretive capital projects. At times the company may provide debt financing as a proprietary investor in the form of bi-laterally negotiated private placements. Bergamo Acquisition has raised investable funds in order to pursue the investment activities listed above. The company has sole fiduciary discretion over these funds and will direct their disposition in line with its overall strategy. In May of 2012, Bergamo Acquisition purchased 100% interest in a European entity for its investing strategies using the Euro currency.
Bergamo Acquisition is dedicated to pursuing alternative energy projects in developing and underdeveloped countries with their cutting-edge products. To this end, the company has taken a 60% interest in Bergamo Energy Inc., of Miami, Florida, a company focused on providing solar energy technologies to sovereign corporate customers in Asian markets. The company’s engineers have developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast energy needs of emerging markets.
Bergamo’s solar powered water pumping system consists of a submersible AC power pump, a PV array to provide solar power, and the company’s own proprietary inverter for energy conversion and system control. Components can be adjusted depending up the water supply being tapped. The complete system is used for agricultural irrigation, centralized daily life water supply stations, and even seawater desalinization and water treatment. Bergamo Energy offers custom water treatment units in a variety of sizes.
For additional information, visit the Bergamo website at www.BergamoCorp.com
Today's Top 3
1-2-3 Stock Alerts
The QualityStocks Public Company Sponsor News